Cell Therapy Manufacturing Market Growth

Cell Therapy Manufacturing Market Growth is anticipated to Cross USD 14,017 million by 2035 | Roots Analysis

According to a recently published report by Roots Analysis, the rising demand for personalized treatments, coupled with the increasing adoption of cell therapies across diverse therapeutic areas and rising investments in advanced biomanufacturing technologies, is driving significant growth in cell therapy manufacturing market

Cell Therapy Manufacturing Market Overview

The cell therapy manufacturing market is expected to reach around USD 14,017 million by 2035, growing at a CAGR of 8.25% during the forecast period till 2035.

Over the years, continuous technological advancements and discoveries have significantly transformed the healthcare landscape. One important advancement is the emergence of cell-based therapies which have shown substantial therapeutic potential while mitigating several toxicity-related challenges associated with conventional pharmacological treatments. Currently, researchers are investigating more than 1,000 cell and gene therapy candidates for the treatment of a myriad of disease indications. Amongst these, around 45 cell-based therapies have already been approved by various regulatory authorities globally.  

Notably, global cell therapy manufacturing market is driven by the strong success of CAR-T cell therapies in treating disorders such as B-cell lymphoma. This can be attributed to the personalized and potentially curative approach of these therapies which enhance therapeutic efficacy and minimize adverse effects, particularly in patients with refractory or relapsed cancers. In addition, rising investments in research and development, improvements in healthcare infrastructure, and more streamlined regulatory pathways are accelerating market growth. As clinical outcomes and manufacturing efficiencies continue to improve, increasing number of cell therapies are expected to gain approval and become commercially accessible to patients in the future.

Browse ~230 figures and 290+ market data tables spread across ~660 pages and detailed Table of Content on “Cell Therapy Manufacturing Market” , till 2035 by Type of Cell Therapy (CAR-T Cell Therapies, Stem Cell Therapies, TCR Cell Therapies, TIL Cell Therapies, Dendritic Cell Therapies and Other Cell Therapies), Source of Cells (Autologous Cells, Allogeneic Cells and Other Cells), Scale of Operation (Clinical Scale and Commercial Scale), Type of Manufacturer (Contract Manufacturing Organizations and In-house Manufacturers) and Geography (North America, Europe, Asia-Pacific and Rest of the World) https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html

Market Drivers

Several factors are propelling cell therapy manufacturing market growth.  The increasing incidence of chronic and rare diseases such as cancer, neurological disorders and autoimmune conditions is significantly boosting the demand for effective and personalized cell-based treatments. The higher success rate of cell therapies compared to traditional treatments further supports their adoption. Additionally, the industry is witnessing a shift from autologous therapies which use patient's own cells but are costly and time-consuming to produce, toward allogenic therapies that utilize cells from healthy donors. Allogeneic therapies offer greater scalability, reduced manufacturing costs, and faster availability, thereby improving accessibility and treatment efficiency across various diseases. This transition is expected to significantly accelerate market expansion in the coming years.

Market Restraints

While the cell therapy manufacturing market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. One of the primary challenges is the establishing and maintaining manufacturing facilities for cell-based therapeutic products require significant capital investment. Moreover, lack of standardized regulatory frameworks for cell therapies manufacturing across different regions results in prolonged approval timelines and increased development costs, which pose barriers to global commercialization. In addition to this, one of the most significant restraints in this field is complexity of the supply chain; cell therapies involve living cells that require careful handling and the manual processes involved elevate risks of failure and impact product quality. This significantly increases the costs associated with storage and transportation compared to conventional pharmaceuticals.

Growth Factors

Despite the aforementioned restraints, several factors continue to drive the cell therapy manufacturing market growth forward. One notable factor is the rapid advancements and integration of automation technologies in cell therapy manufacturing. The incorporation of innovative technologies like CRISPR is further   enhancing efficiency, scalability, and product quality, collectively accelerating expansion within the industry. Moreover, the integration of such automated systems is expected to significantly reduce the production costs associated with cell therapies. Additionally, increasing partnerships between large pharma companies and small biotech firms plays major role in the growth of this domain, with many companies outsourcing manufacturing to reduce the overall cost for new therapies. These are especially beneficial for startups as they get access to state-of-the-art facilities, skilled personnel, and advanced equipment, allowing them to focus on product innovation and commercialization strategy. This reduces the time required to bring therapy from clinical trials to commercialization, giving the company a competitive advantage in fast-moving market expertise and compliance.

Cell Therapy Manufacturing Market Segments

Based on the type of cell therapy, the market is segmented into CAR-T Cell Therapies, Stem Cell Therapies, TCR Cell Therapies, TIL Cell Therapies, Dendritic Cell Therapies and Other Cell Therapies.

• The CAR-T cell therapy segment led the cell therapy manufacturing market, capturing the largest revenue share of 64.1% in the current year.
• The other cell therapies segment, including NK cells and cell modified gene therapies, is anticipated to grow at a higher CAGR of 16.15%, during the forecast period.

Based on the source of cells, the market is segmented into autologous cells, allogeneic cells and other cells.

• The autologous cells segment led the cell therapy manufacturing market, capturing the largest revenue share of 52.0% in the current year.
• In fact, the autologous cells segment is anticipated to grow at a higher CAGR of 9.06%, during the forecast period.

Based on the scale of operation, the market is segmented into clinical and commercial scale.

• The clinical scale segment led the cell therapy manufacturing market, capturing the largest revenue share of 72.9% in the current year.
• The commercial scale segment is anticipated to grow at a higher CAGR of 11.72%, during the forecast period.

Based on type of manufacturer, the market is segmented into contract manufacturing organizations and in-house manufacturers.

• The contract manufacturing organizations segment led the cell therapy manufacturing market, capturing the largest revenue share of 59.1% in the current year.
• The in-house manufacturers segment is anticipated to grow at a higher CAGR of 9.68% during the forecast period.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

• North America dominated the cell therapy manufacturing market, accounting for the largest revenue share of around 43.0% in the current year.
• In fact, the cell therapy manufacturing market in North America is anticipated to demonstrate a higher growth rate of 9.70% during the forecast period.

Key Companies Profiled

The cell therapy manufacturing market report also includes detailed profiles of key players (listed below) that are engaged in the cell therapy manufacturing domain:

• Advanced Therapies
• AGC Biologics
• Astellas Pharma
• Catalent
• Charles River Laboratories
• City of Hope
• Clinical Cell and Vaccine Production Facility (CVPF)
• Evotec
• Fraunhofer Institute for Cell Therapy and Immunology
• ImmunityBio
• Lonza
• Merck Millipore
• Miltenyi Biotec
• Minaris Advanced Therapies
• Newcastle Advanced Therapies
• NHS Blood and Transplant
• OBiO Tech
• Pharmaron
• Rayne Cell Therapy Suite
• Resilience
• Sartorius
• Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
• SK pharmteco (Subsidiary of SK Inc.)
• Takara Bio
• Thermo Fisher Scientific

You Can Download Free Sample PDF Copy of This Report at:

https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com